DENVER, Oct. 17 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation (Amex: AXK) announced today the signing of an agreement with Promega Corporation regarding Accelr8's proprietary OptiChem(R) surface chemistry for use in microarraying slides. The agreement will allow for exploration of new techniques in microarray research using Accelr8 and Promega technologies. According to David Howson, Accelr8's president, "This agreement represents another event for Accelr8 in licensing out our technology components in the microarraying space." "We're gratified that Promega evaluated the alternatives and chose OptiChem because of its performance advantages. We are also pleased to be associated with Promega because of their well-deserved reputation for excellence," said Howson. Microarray techniques allow researchers to study massive numbers of biomolecules in parallel. The technology is based on placing thousands of different types of biomolecules onto a surface such as a glass microarray slide. Microarrays have already had a major impact in fields ranging from cancer research to agriculture, and is rapidly moving from a discovery research tool to broader applications in medical diagnostics. Accelr8's OptiChem coatings provide unique performance advantages that help to make OptiChem-coated slides an enabling component of next generation microarrays. The ongoing revenues from licensing occur in parallel with Accelr8's primary business focus in developing the BACcelr8r(TM) rapid bacterial analysis system. Accelr8 intends the BACcelr8r to become the world's first diagnostic system to provide complete bacterial antibiotic resistance strain identification in 8 hours or less. Conventional culturing typically delays lab results from one to three days, which is inadequate for best management of rapidly progressing, life-threatening infections in critically ill patients. About Accelr8 Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. In addition to its microarraying products, Accelr8 is also developing a rapid clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface coatings, assay processing, and detection technologies.
SOURCE Accelr8 Technology Corporation